首页> 外国专利> METHOD OF PERSONALIZED TREATMENT FOR CARDIOMYOPATHY AND HEART FAILURE AND ASSOCIATED DISEASES BY MEASURING EDEMA AND CACHEXIA/SARCOPENIA

METHOD OF PERSONALIZED TREATMENT FOR CARDIOMYOPATHY AND HEART FAILURE AND ASSOCIATED DISEASES BY MEASURING EDEMA AND CACHEXIA/SARCOPENIA

机译:通过测量水肿和恶病虫病/嗜睡症的心肌病和心力衰竭和相关疾病的个性化治疗方法

摘要

Methods of utilizing quantitative magnetic resonance (QMR) to non-invasively determine and quantify body fluid dynamics [e.g., extracellular water and total water levels] and body compositions (e.g., lean muscle mass and fat mass levels). These levels or changes therein are used as biomarkers to diagnose, prognose, tailor and monitor treatment for conditions that cause or caused by ECW retention (edema), lean muscle mass loss (sarcopenia), and/or fat loss (cachexia), including heart failure (HF) and HF-associated and HF-non-associated edema/sarcopenia/cachexia, kidney disease, liver disease, and other HF complications. Body fluid dynamics and body compositions measurements obtained from QMR technology are used as biomarkers to help a physician's assessment to determine the prognosis and personalized treatment strategies that are tailored for individual patients with heart dysfunction and/or HF, HF-associated conditions, and/or other conditions that cause or caused by edema, sarcopenia, and/or cachexia.
机译:利用定量磁共振(QMR)对非侵入性确定和量化体液动力学的方法[例如细胞外水和总水平]和体组合物(例如,瘦肌肉质量和脂肪质量水平)。其中的这些水平或变化用作生物标志物,用于诊断,预测,定制和监测治疗,用于导致或由ECW保留(水肿),瘦肌肉质量损失(SARCOPENIA)和/或脂肪损失(恶棍),包括心脏失败(HF)和HF相关和HF-无相关水肿/嗜睡/恶病症,肾病,肝病等HF并发症。从QMR技术获得的身体流体动力学和身体组成测量用作生物标志物,以帮助医生评估确定为单个心脏功能障碍和/或HF,HF相关条件和/或为单个患者量身定制的预后和个性化治疗策略和/或导致或由水肿,Sarcopenenia和/或恶病症引起的其他条件。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号